About Repligen Corporation (NASDAQ:RGEN)
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio59.48
Forward P/E Ratio55.59
Sales & Book Value
Annual Sales$104.54 million
Price / Sales14.13
Cash Flow$0.59 per share
Price / Cash57.01
Book Value$13.24 per share
Price / Book2.56
Net Income$11.68 million
Return on Equity7.57%
Return on Assets5.19%
Frequently Asked Questions for Repligen Corporation (NASDAQ:RGEN)
What is Repligen Corporation's stock symbol?
Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen Corporation's earnings last quarter?
Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.04. The biotechnology company earned $36.58 million during the quarter, compared to analyst estimates of $35.69 million. Repligen Corporation had a net margin of 16.93% and a return on equity of 7.57%. The firm's revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.08 EPS. View Repligen Corporation's Earnings History.
When will Repligen Corporation make its next earnings announcement?
What guidance has Repligen Corporation issued on next quarter's earnings?
Repligen Corporation issued an update on its FY17 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of $0.60-0.63 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.59. The company issued revenue guidance of $139-142 million, compared to the consensus revenue estimate of $140.72 million.
Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?
5 analysts have issued 12-month price targets for Repligen Corporation's shares. Their predictions range from $40.00 to $50.00. On average, they expect Repligen Corporation's stock price to reach $45.00 in the next twelve months. View Analyst Ratings for Repligen Corporation.
Who are some of Repligen Corporation's key competitors?
Some companies that are related to Repligen Corporation include Indivior PLC (INDV), Mallinckrodt PLC (MNK), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Macrocure Ltd (MCUR), Check-Cap (CHEK), DARA Biosciences (DARA) and Omthera Pharmaceuticals (OMTH).
Who are Repligen Corporation's key executives?
Repligen Corporation's management team includes the folowing people:
- Karen A. Dawes, Independent Chairperson of the Board (Age 64)
- Tony John Hunt, President, Chief Executive Officer, Director (Age 53)
- Jon K. Snodgres, Chief Financial Officer (Age 51)
- Howard Benjamin Ph.D., Vice President - Business Development (Age 57)
- Nicolas M. Barthelemy, Independent Director (Age 51)
- Glenn L. Cooper M.D., Independent Director (Age 64)
- John G. Cox, Independent Director (Age 54)
- Glenn P. Muir, Independent Director (Age 58)
- Thomas F. Ryan Jr., Independent Director (Age 75)
Who owns Repligen Corporation stock?
Repligen Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include TimesSquare Capital Management LLC (6.79%), Conestoga Capital Advisors LLC (3.89%), Stephens Investment Management Group LLC (2.70%), Dimensional Fund Advisors LP (1.93%), Macquarie Group Ltd. (2.21%) and Palisade Capital Management LLC NJ (1.76%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen Corporation.
Who sold Repligen Corporation stock? Who is selling Repligen Corporation stock?
Repligen Corporation's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, TimesSquare Capital Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd., Prudential Financial Inc., Pier Capital LLC, Schroder Investment Management Group and North Star Asset Management Inc.. Company insiders that have sold Repligen Corporation company stock in the last year include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen Corporation.
Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?
Repligen Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Conestoga Capital Advisors LLC, Mackenzie Financial Corp, Perceptive Advisors LLC, Assenagon Asset Management S.A., Kornitzer Capital Management Inc. KS, Stephens Investment Management Group LLC and American Century Companies Inc.. View Insider Buying and Selling for Repligen Corporation.
How do I buy Repligen Corporation stock?
Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen Corporation's stock price today?
One share of Repligen Corporation stock can currently be purchased for approximately $33.91.
How big of a company is Repligen Corporation?
Repligen Corporation has a market capitalization of $1.50 billion and generates $104.54 million in revenue each year. The biotechnology company earns $11.68 million in net income (profit) each year or $0.59 on an earnings per share basis. Repligen Corporation employs 236 workers across the globe.
How can I contact Repligen Corporation?
Repligen Corporation's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen Corporation (RGEN)MarketBeat's community ratings are surveys of what our community members think about Repligen Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Repligen Corporation (NASDAQ:RGEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$45.00 (32.70% upside)|
Consensus Price Target History for Repligen Corporation (NASDAQ:RGEN)
Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/13/2017||CL King||Initiated Coverage||Buy -> Buy||$41.00||N/A|
|10/19/2017||Jefferies Group LLC||Reiterated Rating||Hold||$40.00||N/A|
|10/2/2017||First Analysis||Upgrade||Equal Weight -> Overweight||$47.00||Medium|
|7/21/2017||William Blair||Initiated Coverage||Outperform -> Outperform||Low|
|6/23/2017||Janney Montgomery Scott||Boost Price Target||$42.00 -> $47.00||High|
|2/22/2016||Craig Hallum||Initiated Coverage||Buy||N/A|
Earnings History and Estimates Chart for Repligen Corporation (NASDAQ:RGEN)
Earnings History by Quarter for Repligen Corporation (NASDAQ RGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/28/2018|| || || || || || || || |
|11/9/2017||Q3 2017||$0.11||$0.15||$35.69 million||$36.58 million||View||N/A|
|8/3/2017||Q2 2017||$0.15||$0.20||$31.72 million||$32.40 million||View||Listen|
|5/4/2017||3/31/2017||$0.13||$0.15||$29.28 million||$30.59 million||View||Listen|
|2/22/2017||Q416||$0.07||$0.08||$24.05 million||$25.60 million||View||Listen|
|11/3/2016||Q316||$0.08||$0.08||$24.39 million||$24.70 million||View||N/A|
|8/4/2016||Q216||$0.13||$0.16||$24.75 million||$29.20 million||View||N/A|
|5/5/2016||Q116||$0.10||$0.12||$22.54 million||$25.10 million||View||N/A|
|2/25/2016||Q415||$0.07||$0.07||$19.84 million||$21.40 million||View||Listen|
|11/5/2015||Q315||$0.08||$0.08||$20.50 million||$19.80 million||View||N/A|
|8/6/2015||Q215||$0.08||$0.11||$20.05 million||$21.50 million||View||N/A|
|5/7/2015||Q115||$0.07||$0.09||$18.20 million||$20.82 million||View||N/A|
|3/13/2015||Q414||$0.04||($0.01)||$14.70 million||$15.40 million||View||N/A|
|11/6/2014||Q314||$0.04||$0.04||$15.60 million||$15.30 million||View||N/A|
|8/11/2014||Q114||$0.06||$0.09||$14.90 million||$15.60 million||View||N/A|
|5/8/2014||Q1||$0.07||$0.13||$15.14 million||$16.33 million||View||Listen|
|3/6/2014||Q413||$0.14||$0.10||$15.88 million||$10.40 million||View||Listen|
|11/7/2013||Q313||$0.13||$0.18||$16.27 million||$18.80 million||View||Listen|
|8/1/2013||Q2 2013||$0.10||$0.14||$15.97 million||$17.50 million||View||Listen|
|5/2/2013||Q1 2013||$0.07||$12.82 million||$16.46 million||View||Listen|
|11/8/2012||Q312||$0.06||$8.63 million||$15.10 million||View||N/A|
Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
2017 EPS Consensus Estimate: $0.54
2018 EPS Consensus Estimate: $0.70
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Repligen Corporation (NASDAQ RGEN)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 81.26%
Insider Trades by Quarter for Repligen Corporation (NASDAQ RGEN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/21/2017||Karen A Dawes||Director||Sell||2,521||$34.12||$86,016.52|| |
|3/20/2017||Howard Benjamin||VP||Sell||12,216||$34.62||$422,917.92|| |
|3/20/2017||Thomas F Ryan Jr||Director||Sell||4,000||$34.83||$139,320.00|| |
|3/17/2017||Jon Snodgres||CFO||Sell||1,909||$34.91||$66,643.19|| |
|11/28/2016||Anthony Hunt||CEO||Sell||5,000||$33.12||$165,600.00|| |
|9/14/2016||Thomas F Ryan Jr||Director||Sell||2,700||$32.58||$87,966.00|| |
|6/30/2016||Thomas F Ryan Jr||Director||Sell||5,000||$26.60||$133,000.00|| |
|6/28/2016||Thomas F Ryan Jr||Director||Sell||10,000||$24.59||$245,900.00|| |
|5/11/2016||Howard Benjamin||VP||Sell||2,889||$26.72||$77,194.08|| |
|6/9/2015||Howard Benjamin||VP||Sell||35,000||$38.14||$1,334,900.00|| |
|5/11/2015||Walter C Herlihy||CEO||Sell||104,569||$37.94||$3,967,347.86|| |
|5/8/2015||Thomas F Ryan Jr||Director||Sell||20,000||$37.19||$743,800.00|| |
|3/23/2015||Walter C Herlihy||CEO||Sell||24,536||$31.78||$779,754.08|| |
|3/19/2015||James R Rusche||SVP||Sell||14,650||$33.30||$487,845.00|| |
|3/19/2015||Thomas F Ryan Jr||Director||Sell||10,000||$32.62||$326,200.00|| |
|3/19/2015||Walter C Herlihy||CEO||Sell||49,695||$33.08||$1,643,910.60|| |
|3/18/2015||Howard Benjamin||VP||Sell||15,795||$32.63||$515,390.85|| |
|11/19/2014||Walter C Herlihy||CEO||Sell||51,386||$23.43||$1,203,973.98|| |
|11/13/2014||Thomas F Ryan Jr||Director||Sell||10,000||$23.81||$238,100.00|| |
|11/11/2014||Howard Benjamin||VP||Sell||30,000||$23.56||$706,800.00|| |
|11/10/2014||Michael A Griffith||Director||Sell||23,342||$22.90||$534,531.80|| |
|8/13/2014||Howard Benjamin||VP||Sell||40,000||$20.34||$813,600.00|| |
|6/27/2014||Thomas F Ryan Jr||Director||Sell||10,000||$22.41||$224,100.00|| |
|6/24/2014||Thomas F Ryan Jr||Director||Sell||10,000||$21.78||$217,800.00|| |
|6/11/2014||Walter C Herlihy||CEO||Sell||60,335||$20.11||$1,213,336.85|| |
|6/9/2014||James R Rusche||SVP||Sell||30,000||$20.19||$605,700.00|| |
|6/6/2014||Daniel P Witt||SVP||Sell||47,709||$20.56||$980,897.04|| |
|4/15/2014||Daniel P Witt||SVP||Buy||10,000||$3.05||$30,500.00|| |
|8/8/2013||James R Rusche||SVP||Sell||30,000||$10.01||$300,300.00|| |
|6/21/2013||Karen A Dawes||Director||Buy||1,000||$7.70||$7,700.00|| |
|5/17/2013||Thomas F Ryan Jr||Director||Sell||21,000||$8.97||$188,370.00|| |
|5/15/2013||Thomas F Ryan Jr||Director||Sell||86,039||$9.01||$775,211.39|| |
|5/15/2013||Walter C Herlihy||CEO||Sell||40,000||$8.97||$358,800.00|| |
|9/21/2012||Glenn L Md Cooper||Director||Buy||10,000||$6.09||$60,900.00|| |
|8/16/2012||Michael A Griffith||Director||Buy||2,000||$4.88||$9,760.00|| |
Latest Headlines for Repligen Corporation (NASDAQ RGEN)
Repligen Corporation (NASDAQ RGEN) Chart for Thursday, November, 23, 2017